On September 4, 2020 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), reported that management will be participating in the following investor conferences this month (Press release, Infinity Pharmaceuticals, SEP 4, 2020, View Source [SID1234564488]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Wells Fargo Securities Annual Healthcare Conference
Date:
Wednesday, September 9th
Time:
3:30 pm Eastern Time
Webcast:
H.C. Wainwright Global Investment Conference
Date:
Tuesday, September 15th
Time:
2:00 pm Eastern Time
Webcast:
A live webcast of each presentation will be available on the Investors/Media section of Infinity’s website at www.infi.com and will be available for 30 days following the event.